IGI Logo

Orchid Pharma is currently trading at Rs. 1040.85, up by 42.50 points or 4.26% from its previous closing of Rs. 998.35 on the BSE.

The scrip opened at Rs. 1000.00 and has touched a high and low of Rs. 1056.75 and Rs. 1000.00 respectively. So far 4938 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1358.80 on 26-Feb-2024 and a 52 week low of Rs. 411.05 on 09-Jun-2023.

Last one week high and low of the scrip stood at Rs. 1056.75 and Rs. 936.15 respectively. The current market cap of the company is Rs. 5153.31 crore.

The promoters holding in the company stood at 69.84%, while Institutions and Non-Institutions held 19.69% and 10.47% respectively.

Orchid Pharma has received Drugs Controller General of India (DCGI) approval for the manufacturing and marketing of its invented New Chemical Entity Active Pharmaceutical Ingredient (API), Enmetazobactam.

DCGI has also granted permission to manufacture and market Finished Dosage Form (FDF) of Cefepime and Enmetazobactam as a dry powder injectable. This formulation is indicated for the treatment of complicated Urinary Tract Infections (cUTI) including acute Pyelonephritis, Hospital-Acquired Pneumonia (HAP) including Ventilator-associated pneumonia (VAP), and Bacteremia when it is associated or suspected to be associated with either complicated urinary tract infections or hospital-acquired pneumonia. With this approval, Orchid Pharma intends to improve the treatment landscape for serious infections in India, providing patients with access to advanced and effective therapy options.

Orchid Pharma, established as an export-oriented unit (EOU), is a vertically integrated company spanning the entire pharmaceutical value chain from discovery to delivery with established credentials in research, manufacturing and marketing.